Chimeric Therapeutics

Chimeric Therapeutics is developing ground-breaking CAR-T cell therapies for solid tumors based on scientific research conducted by leading US CAR-T experts at the City of Hope (COH) Cancer Centre in Los Angeles. Its CLTXCART technology incorporates chlorotoxin (CLTX), a peptide derived from scorpion toxin, as a novel CAR tumor recognition domain. This domain extends the range of CAR-T cell targeting in solid tumors.

Potent antitumor activity against glioblastoma (GBM) has been established in preclinical models. Currently undergoing Phase 1 clinical trials in GBM at COH, CLTX CAR-T has significant drug administration benefits since it
can be delivered during an outpatient visit.

CLTX CAR-T cells differ from other GBM-targeting immunotherapies by its specific and broad recognition of patient tumors and of the majority of cells within these tumors. CLTX CAR-T cells target GBM through recognition of a
receptor complex composed of membrane-bound matrix metalloprotease 2 (MMP2) and involving the chloride channel CLC3.

CLTX CAR-T cells do not exhibit off-tumor recognition of normal human or murine cells/tissues in preclinical models, consistent with the documented safety of administering other CLTX-containing therapeutic agents in
humans.

The CLTX peptide has also demonstrated safety and specificity in clinical testing as a radiotherapy delivery conjugate and as an imaging agent in fluorescence-guided surgery for recurrent/refractory GBM.

62 Lygon St, LEVEL 3, Carlton, Victoria 3053, AU